Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05600842 · ClinicalTrials.gov registry record
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
A clinical trial of HPV Positive Oropharyngeal Squamous Cell Carcinoma, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- 111
- Enrollment target
- 1
- Study location
NCT05600842 is a study of HPV Positive Oropharyngeal Squamous Cell Carcinoma that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 111 participants, above the 85-participant average among 16 other HPV Positive Oropharyngeal Squamous Cell Carcinoma trials with a reported enrollment target (31% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05600842, a study of HPV Positive Oropharyngeal Squamous Cell Carcinoma, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- 111 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-arm, observational registry study determining the effects of reduced radiation dose in select patients with human papillomavirus (HPV) positive oropharyngeal cancer.
Conditions Studied
Interventions
- RADIATION Intensity-Modulated Radiation Therapy (IMRT)
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center, University of California, Irvine - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2022-11-03 |
| Est. Completion | 2026-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05600842
The ClinicalTrials.gov registry entry for NCT05600842 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 85-participant average among 16 other HPV Positive Oropharyngeal Squamous Cell Carcinoma trials with a reported enrollment target (31% higher). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HPV Positive Oropharyngeal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Intensity-Modulated Radiation Therapy (IMRT) is the first listed.
NCT05600842 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05600842 about?
NCT05600842 is a clinical study titled "De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx". This is a single-arm, observational registry study determining the effects of reduced radiation dose in select patients with human papillomavirus (HPV) positive oropharyngeal cancer.
What is the current status of trial NCT05600842?
This trial is currently recruiting. The enrollment target is 111 participants. The study started on 2022-11-03. Estimated completion is 2026-11.
What conditions does trial NCT05600842 study?
This clinical trial studies the following conditions: HPV Positive Oropharyngeal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05600842?
The interventions under investigation include: Intensity-Modulated Radiation Therapy (IMRT) (RADIATION).
Who is sponsoring clinical trial NCT05600842?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05600842 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV Positive Oropharyngeal Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
RECRUITING · Phase 1
-
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
RECRUITING · Phase 1
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
-
Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.